

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 July 2001 (12.07.2001)

PCT

(10) International Publication Number  
**WO 01/49670 A1**

(51) International Patent Classification<sup>7</sup>: C07D 279/26,  
A61K 31/54, A61P 9/00

P. [CA/CA]; 3963 West 24th Avenue, Vancouver, British  
Columbia V6S 1M1 (CA).

(21) International Application Number: PCT/CA00/01586

(74) Agents: **ROBINSON, J., Christopher** et al.; Fetherston-  
haugh & Co., Suite 2200, 650 West Georgia Street, Van-  
couver Centre, Box 11560, Vancouver, British Columbia  
V6B 4N8 (CA).

(22) International Filing Date:

29 December 2000 (29.12.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09/476,928

30 December 1999 (30.12.1999) US


(71) Applicant (for all designated States except US): **NEU-  
ROMED TECHNOLOGIES, INC.** [CA/CA]; 2389  
Health Science Mall, Suite 301, The University of British  
Columbia, Vancouver, British Columbia V6T 1Z4 (CA).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: 5,10-DIHYDROACRIDINES AS CALCIUM CHANNEL BLOCKERS



(57) Abstract: Compounds of formula (1a) or (1b) or salts thereof, wherein Z is N or CH; wherein n is 0 or 1; X<sup>1</sup> and X<sup>2</sup> are linkers; Ar represents one or two substituted or unsubstituted aromatic or heteroaromatic rings, and Cy represents one or two substituted or unsubstituted aliphatic cyclic or heterocyclic moieties, or consists of one substituted or unsubstituted aliphatic cyclic or heterocyclic moiety and one substituted or unsubstituted aromatic or heteroaromatic moiety, Y is O, S, NR or CR<sub>2</sub> where R is H or alkyl (1-6C); each 1<sup>1</sup> and 1<sup>2</sup> is independently 0-4; 1<sup>3</sup> is 0 or 1; each of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is independently alkyl (1-6C), aryl (6-10C) or arylalkyl (7-16C) optionally containing 1-4 heteroatoms selected from the group consisting of halo, N, P, O, and S or may independently be halo, OR, SR, NR<sub>2</sub>, OOCR, NROCR, COR, COOR, CONR<sub>2</sub>, CF<sub>3</sub>, CN or NO<sub>2</sub>, wherein R is H or alkyl (1-6C), and wherein the dotted lines represent optional  $\pi$ -bonds, or compounds of formulas (1a) or (1b) where (X<sup>2</sup>)<sub>n</sub>Ar or (X<sup>2</sup>)<sub>n</sub>Cy is replaced by alkyl (1-6C) are useful in methods to block calcium channels.



WO 01/49670 A1



**Published:**

- *With international search report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## 5,10-DIHYDROACRIDINES AS CALCIUM CHANNEL BLOCKERS

Technical Field

5           The invention relates to compounds useful in treating conditions associated with calcium channel function. More specifically, the invention concerns compounds containing a fused ring system and 6-membered heterocyclic moieties that are useful in treatment of conditions such as stroke and pain.

Background Art

10           Native calcium channels have been classified by their electrophysiological and pharmacological properties as T, L, N, P and Q types (for reviews see McCleskey, E.W. *et al. Curr Topics Membr* (1991) 39:295-326, and Dunlap, K. *et al. Trends Neurosci* (1995) 18:89-98). T-type (or low voltage-activated) channels describe a broad class of molecules that  
15           transiently activate at negative potentials and are highly sensitive to changes in resting potential. The L, N, P and Q-type channels activate at more positive potentials (high voltage activated) and display diverse kinetics and voltage-dependent properties. There is some overlap in biophysical properties of the high voltage-activated channels, consequently pharmacological profiles are useful to further distinguish them. L-type channels are sensitive to dihydropyridine agonists and  
20           antagonists, N-type channels are blocked by the *Conus geographus* peptide toxin,  $\omega$ -conotoxin GVIA, and P-type channels are blocked by the peptide  $\omega$ -agatoxin IVA from the venom of the funnel web spider, *Agelenopsis aperta*. A fourth type of high voltage-activated calcium channel (Q-type) has been described, although whether the Q- and P-type channels are distinct molecular entities is controversial (Sather, W.A. *et al. Neuron* (1995) 11:291-303; Stea, A. *et al. Proc Natl Acad Sci USA* (1994) 91:10576-10580; Bourinet, E. *et al. Nature Neuroscience* (1999) 2:407-415). Several types of calcium conductances do not fall neatly into any of the above categories and there is variability of properties even within a category suggesting that additional calcium channels subtypes remain to be classified.

25           Biochemical analyses show that neuronal high voltage activated calcium channels are heterooligomeric complexes consisting of three distinct subunits ( $\alpha_1$ ,  $\alpha_2\delta$  and  $\beta$ ) (reviewed by  
30           De Waard, M. *et al. Ion Channels* (1997) vol. 4, Narahashi, T. ed. Plenum Press, NY). The  $\alpha_1$  subunit is the major pore-forming subunit and contains the voltage sensor and binding sites for calcium channel antagonists. The mainly extracellular  $\alpha_2$  is disulfide-linked to the

transmembrane  $\delta$  subunit and both are derived from the same gene and are proteolytically cleaved *in vivo*. The  $\beta$  subunit is a nonglycosylated, hydrophilic protein with a high affinity of binding to a cytoplasmic region of the  $\alpha_1$  subunit. A fourth subunit,  $\gamma$ , is unique to L-type calcium channels expressed in skeletal muscle T-tubules. The isolation and characterization of  $\gamma$ -subunit-encoding cDNAs is described in U.S. Patent No. 5,386,025 which is incorporated herein by reference.

Recently, each of these  $\alpha_1$  subtypes has been cloned and expressed, thus permitting more extensive pharmacological studies. These channels have been designated  $\alpha_{1A}$ - $\alpha_{1I}$  and  $\alpha_{1S}$  and correlated with the subtypes set forth above.  $\alpha_{1A}$  channels are of the P/Q type;  $\alpha_{1B}$  represents N;  $\alpha_{1C}$ ,  $\alpha'_{1D}$ ,  $\alpha_{1F}$  and  $\alpha_{1S}$  represent L;  $\alpha_{1E}$  represents a novel type of calcium conductance, and  $\alpha_{1G}$ - $\alpha_{1I}$  represent members of the T-type family, reviewed in Stea, A. *et al.* in Handbook of Receptors and Channels (1994), North, R.A. ed. CRC Press; Perez-Reyes, *et al.* *Nature* (1998) 391:896-900; Cribbs, L.L. *et al.* *Circulation Research* (1998) 83:103-109; Lee, J.H. *et al.* *Journal of Neuroscience* (1999) 19:1912-1921.

Further details concerning the function of N-type channels, which are presynaptic channels, have been disclosed, for example, in U.S. Patent No. 5,623,051, the disclosure of which is incorporated herein by reference. As described, N-type channels possess a site for binding syntaxin, a protein anchored in the presynaptic membrane. Blocking this interaction also blocks the presynaptic response to calcium influx. Thus, compounds that block the interaction between syntaxin and this binding site would be useful in neural protection and analgesia. Such compounds have the added advantage of enhanced specificity for presynaptic calcium channel effects.

U.S. Patent No. 5,646,149 describes calcium channel antagonists of the formula A-Y-B wherein B contains a piperazine or piperidine ring directly linked to Y. An essential component of these molecules is represented by A, which must be an antioxidant; the piperazine or piperidine itself is said to be important. The exemplified compounds contain a benzhydryl substituent, based on known calcium channel blockers (see below). U.S. Patent No. 5,703,071 discloses compounds said to be useful in treating ischemic diseases. A mandatory portion of the molecule is a tropolone residue; among the substituents permitted are piperazine derivatives, including their benzhydryl derivatives. U.S. Patent No. 5,428,038 discloses compounds which are said to exert a neural protective and antiallergic effect. These compounds are coumarin derivatives which may include derivatives of piperazine and other six-membered heterocycles. A permitted substituent on the heterocycle is diphenylhydroxymethyl. Thus, approaches in the art for various indications which may involve calcium channel blocking activity have employed


compounds which incidentally contain piperidine or piperazine moieties substituted with benzhydryl but mandate additional substituents to maintain functionality.

Certain compounds containing both benzhydryl moieties and piperidine or piperazine are known to be calcium channel antagonists and neuroleptic drugs. For example, Gould, R.J. *et al. Proc Natl Acad Sci USA* (1983) 80:5122-5125 describes antischizophrenic neuroleptic drugs such as lidoflazine, fluspirilene, pimozide, clopimozide, and penfluridol. It has also been shown that fluspirilene binds to sites on L-type calcium channels (King, V.K. *et al. J Biol Chem* (1989) 264:5633-5641) as well as blocking N-type calcium current (Grantham, C.J. *et al. Brit J Pharmacol* (1944) 111:483-488). In addition, Lomerizine, developed by Kanebo KK, is a known non-specific calcium channel blocker. A review of publications concerning Lomerizine is found in Dooley, D., *Current Opinion in CPNS Investigational Drugs* (1999) 1:116-125.

The present invention is based on the recognition that compounds comprising a six-membered heterocyclic ring containing at least one nitrogen coupled to a constrained fused ring moiety and to a hydrophobic cluster (each optionally through a linker) provide calcium channel blocking activity. These compounds are useful, for example, for treating stroke and pain. By focusing on these moieties, compounds useful in treating indications associated with unwanted calcium channel activity and combinatorial libraries that contain these compounds can be prepared.

## Disclosure of the Invention


The invention relates to compounds useful in treating conditions such as stroke, head trauma, migraine, chronic, neuropathic and acute pain, epilepsy, hypertension, cardiac arrhythmias, and other indications associated with calcium metabolism, including synaptic calcium channel-mediated functions. The compounds of the invention are constrained fused ring derivatives of piperidine or piperazine linked to hydrophobic substituents which enhance the calcium channel blocking activity. Thus, in one aspect, the invention is directed to therapeutic methods that employ compounds of the formulas



SUBSTITUTE SHEET (RULE 26)

- 4 -

or



wherein Z is N or CH;

wherein n is 0 or 1;

$X^1$  and  $X^2$  are linkers;

Ar represents one or two substituted or unsubstituted aromatic or heteroaromatic rings,

and

Cy represents one or two substituted or unsubstituted aliphatic cyclic or heterocyclic moieties, or consists of one substituted or unsubstituted aliphatic cyclic or heterocyclic moiety and one substituted or unsubstituted aromatic or heteroaromatic moiety,

Y is O, S, NR or  $CR_2$  where R is H or alkyl (1-6C);

each  $l^1$  and  $l^2$  is independently 0-4;

$l^3$  is 0 or 1;

each of  $R^1$ ,  $R^2$  and  $R^3$  is independently alkyl (1-6C), aryl (6-10C) or arylalkyl (7-16C)

optionally containing 1-4 heteroatoms selected from the group consisting of halo, N, P, O, and S or may independently be halo, OR, SR,  $NR_2$ ,  $OOCR$ ,  $NROCR$ , COR, COOR,  $CONR_2$ ,  $CF_3$ , CN or  $NO_2$ , wherein R is H or alkyl (1-6C), and

wherein the dotted lines represent optional  $\pi$ -bonds, or

compounds of formulas (1a) or (1b) where  $(X^2)_nAr$  or  $(X^2)_nCy$  is replaced by substituted or unsubstituted alkyl (1-6C).

The invention is directed to methods to antagonize calcium channel activity using the compounds of formulas (1a) or (1b) and thus to treat associated conditions. It will be noted that the conditions may be associated with abnormal calcium channel activity, or the subject may have normal calcium channel function which nevertheless results in an undesirable physical or metabolic state that can be benefited by lowering calcium transport. In another aspect, the invention is directed to pharmaceutical compositions containing these compounds.

The invention is also directed to combinatorial libraries containing the compounds of formulas (1a) or (1b) and to methods to screen these libraries for members containing

SUBSTITUTE SHEET (RULE 26)

particularly potent calcium channel blocking activity including channel blocking activity of particular types or for members that antagonize other ion channels.

#### Modes of Carrying out the Invention

5           The compounds of formulas (1a) or (1b), useful in the methods of the invention, exert their desirable effects through their ability to antagonize the activity of calcium channels, including those which are synaptic in their activity. While the compounds of formulas (1a) or (1b) generally have this activity, the availability of a multiplicity of calcium channel blockers permits a nuanced selection of compounds for particular disorders. Thus, the availability of this

10           class of compounds provides not only a genus of general utility in indications that are affected by excessive calcium channel activity, but also provides a large number of compounds which can be mined and manipulated for specific interaction with particular forms of calcium or other channels. The availability of recombinantly produced calcium channels of the  $\alpha_{1A}$ - $\alpha_{1I}$  and  $\alpha_{1S}$  types set forth above, facilitates this selection process. Dubel, S.J. *et al. Proc Natl Acad Sci*

15           *USA* (1992) 89:5058-5062; Fujita, Y. *et al. Neuron* (1993) 10:585-598; Mikami, A. *et al. Nature* (1989) 340:230-233; Mori, Y. *et al. Nature* (1991) 350:398-402; Snutch, T.P. *et al. Neuron* (1991) 7:45-57; Soong, T.W. *et al. Science* (1993) 260:1133-1136; Tomlinson, W.J. *et al. Neuropharmacology* (1993) 32:1117-1126; Williams, M.E. *et al. Neuron* (1992) 8:71-84; Williams, M.E. *et al. Science* (1992) 257:389-395; Perez-Reyes, *et al. Nature* (1998) 391:896-

20           900; Cribbs, L.L. *et al. Circulation Research* (1998) 83:103-109; Lee, J.H. *et al. Journal of Neuroscience* (1999) 19:1912-1921.

          Thus, while it is known that calcium channel activity is involved in a multiplicity of disorders, the types of channels associated with particular conditions is the subject of ongoing data collection. The association of N-type channels in conditions associated with neural

25           transmission would indicate that compounds which target N-type receptors are useful in these

other psychoses. Cardiovascular conditions affected by calcium flux include hypertension and cardiac arrhythmias.


The availability of the libraries containing the compounds of formulas (1a) or (1b) also provides a source of compounds which may be screened for activity with regard to calcium channels and other ion channels. Other ion channels are also associated with conditions that are susceptible to treatment. Blockers of sodium channels, for example, are useful as local anesthetics, and in treating cardiac arrhythmias, as anticonvulsants, and in treating hyperkalemic periodic paralysis. Potassium channel blockers are useful in treating hypertension and cardiac arrhythmias; various other receptors are associated with psychoses, schizophrenia, depression, and apnea. Thus, the library of compounds of the invention is useful in standard screening techniques as a source of effective pharmaceutical compounds.

### Synthesis

The compounds of the invention may be synthesized using conventional methods.

Illustrative of such methods are the following schemes.

Scheme 1 (Phenanthrothiazine Derivatives)




As shown in Scheme 1, phenanthrothiazine or the corresponding compound wherein S is replaced by O, NR or  $\text{CR}_2$ , is reacted with butyllithium and then treated with the desired mesylate to generate the intermediate wherein the linker  $\text{X}^1$  is coupled to the nitrogen of the phenanthrothiazine. In the instance wherein Y is NR, especially NH, and where the phenylene rings are substituted, mixtures of isomers may result, which may then be separated as desired. The resulting coupled compound is then reacted with the desired piperazine or piperidine to generate the compounds of the invention. The mesylate required for step 1 can readily be generated by treating the corresponding omega-hydroxybromide with methylsulfonyl chloride.

For compounds wherein Z is CH, the appropriate substituted piperidine can be prepared by



treating the corresponding pyridone with the appropriate amine and reducing with a mild reducing agent, as shown in Scheme 2.

Scheme 2



### Preferred Embodiments

The compounds of formulas (1a) or (1b) are defined as shown in terms of the embodiments of their various substituents:

Y may be O, S, NR or  $\text{CR}_2$ ; preferably each R is H. More preferably, Y is S.

Z may be N or CH.

Preferably, each of  $\text{R}^1$  and  $\text{R}^2$  is independently alkyl (1-6C), arylalkyl (7-16C), halo, OR, SR,  $\text{NR}_2$ ,  $\text{OOCR}$ ,  $\text{NROCR}$ , COR, COOR or  $\text{CONR}_2$  wherein each R is independently H or alkyl (1-6C) or may be CN,  $\text{CF}_3$  or  $\text{NO}_2$  (the "substituents"). Preferred embodiments of  $\text{I}^1$  and  $\text{I}^2$  include those 1) where one substituent is ortho or meta to Y and 2) where two substituents are in the positions meta and para to Y. Especially preferred forms of  $\text{R}^1$  and  $\text{R}^2$  include phenyl, phenylalkyl, F, Cl, Br, I,  $\text{CF}_3$ , OR,  $\text{NR}_2$  and alkyl. Particularly preferred are F, OMe,  $\text{NH}_2$ ,  $\text{NMe}_2$ ,  $\text{NHOAc}$ ,  $\text{CONH}_2$ , Br, COOEt, and COOMe.

$\text{R}^3$  may be alkyl (1-6C) aryl (6-10C) or arylalkyl (7-16C) optionally containing 1-4 heteroatoms selected from the group consisting of N, P, O, S, and halo; preferred embodiments of  $\text{R}^3$  include methyl.  $\text{R}^3$  may also include halo, OR, SR,  $\text{NR}_2$ ,  $\text{OOCR}$ ,  $\text{NROCR}$ , COR, COOR or  $\text{CONR}_2$  wherein each R is independently H or alkyl (1-6C) or may be CN,  $\text{CF}_3$  or  $\text{NO}_2$ . Typically,  $\text{I}^3$  is 0 or 1, preferably 0.

As n may be 0 or 1,  $\text{X}^2$  may be present or not.  $\text{X}^1$  and  $\text{X}^2$  are suitable linkers containing 1-10C which may be saturated or unsaturated and may contain a ring. The linker may also contain one or two heteroatoms selected from N, O and S and may be substituted with the "substituents" listed above. Preferred embodiments of  $\text{X}^1$  and  $\text{X}^2$  include  $-(\text{CH}_2)_a-$  wherein a is 1-10, preferably 1-6,  $-(\text{CH}_2)_b\text{CO}-$  or  $-\text{CO}(\text{CH}_2)_b$  where b is 1-9, and  $-(\text{CH}_2)_c\text{CH}=\text{CH}-$  where c is 0-4. Also preferred particularly for  $\text{X}^2$  is  $-\text{NH}(\text{CH}_2)_d-$  or  $-\text{NHCO}(\text{CH}_2)_d-$  where d is 1-8, when Z is CH.

Thus, formulas (1a) and (1b) are similar, except that compounds of formula (1a) contain aromatic substituents linked to the heterocyclic 6-membered ring and those of (1b) contain aliphatic cyclic or heterocyclic moieties. In each case, preferably when  $X^2$  is present,  $X^2$  represents a linker which spaces the Ar or Cy moiety from Z at a distance of 3-20Å, and may contain at least one heteroatom which is nitrogen or oxygen. Included in such linkers are amines and carbonyl functionalities, including amides. The linker may also be unsaturated or may be an alkylene group. Typically,  $X^2$  is  $(CH_2)_{1-10}$  or  $-CO(CH_2)_{1-9}-$  or  $(CH_2)_{1-5}-CH=CH-(CH_2)_{0-3}-$ . Similarly,  $X^1$  spaces the constrained fused ring system from the nitrogen of the heterocyclic ring at a distance of 3-20Å.

For  $X^2$ , when there are two aromatic or heterocyclic or other cyclic moieties,  $X^2$  must accommodate this and a typical embodiment is  $-(CH_2)_{0-9}-CH$ .  $X^2$  may also contain a  $\pi$ -bond, e.g.,  $-(CH_2)_{0-5}CH=C$ , for such accommodation.

In preferred forms of formulas (1a) and (1b),  $X^1$  is  $(CH_2)_{1-5}CO(CH_2)_{0-3}$  or  $(CH_2)_{1-5}NH(CH_2)_{1-3}$  or  $(CH_2)_{1-5}CONH(CH_2)_{1-3}$ .

Preferred embodiments for  $X^2$  are similar except that in instances where Ar or Cy represent two rings, the two rings are coupled to CH or to a  $\pi$ -bonded carbon as the terminal portion of the linker  $X^2$ .

Although it is preferred that  $l^1$  and  $l^2$  are both 0, substitution by  $R^1$  and  $R^2$  in the constrained fused ring system is permitted as set forth in the description of the invention above.

It is believed that halogenation of the compounds of the invention is helpful in modulating the *in vivo* half-life, and it may be advantageous to include halogen substituents as  $R^1$  and  $R^2$ . In formulas (1a) and (1b), such substituents may also be included on Ar and Cy.

The invention compounds may also be supplied as pharmaceutically acceptable salts. Pharmaceutically acceptable salts include the acid addition salts which can be formed from inorganic acids such as hydrochloric, sulfuric, and phosphoric acid or from organic acids such as acetic, propionic, glutamic, glutaric, as well as acid ion-exchange resins.

### Utility and Administration

For use as treatment of human and animal subjects, the compounds of the invention can be formulated as pharmaceutical or veterinary compositions. Depending on the subject to be treated, the mode of administration, and the type of treatment desired -- e.g., prevention, prophylaxis, therapy; the compounds are formulated in ways consonant with these parameters. A summary of such techniques is found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, PA, incorporated herein by reference.

In general, for use in treatment, the compounds of formulas (1a) and (1b) may be used alone, as mixtures of two or more compounds of formulas (1a) and (1b) or in combination with other pharmaceuticals. Depending on the mode of administration, the compounds will be formulated into suitable compositions to permit facile delivery.

5        Formulations may be prepared in a manner suitable for systemic administration or topical or local administration. Systemic formulations include those designed for injection (e.g., intramuscular, intravenous or subcutaneous injection) or may be prepared for transdermal, transmucosal, or oral administration. The formulation will generally include a diluent as well as, in some cases, adjuvants, buffers, preservatives and the like. The compounds can be  
10       administered also in liposomal compositions or as microemulsions.

For injection, formulations can be prepared in conventional forms as liquid solutions or suspensions or as solid forms suitable for solution or suspension in liquid prior to injection or as emulsions. Suitable excipients include, for example, water, saline, dextrose, glycerol and the like. Such compositions may also contain amounts of nontoxic auxiliary substances such as  
15       wetting or emulsifying agents, pH buffering agents and the like, such as, for example, sodium acetate, sorbitan monolaurate, and so forth.

Various sustained release systems for drugs have also been devised. See, for example, U.S. Patent No. 5,624,677.

20       Systemic administration may also include relatively noninvasive methods such as the use of suppositories, transdermal patches, transmucosal delivery and intranasal administration. Oral administration is also suitable for compounds of the invention. Suitable forms include syrups, capsules, tablets, as in understood in the art.

For administration to animal or human subjects, the dosage of the compounds of the invention is typically 0.1-15 mg/kg, preferably 0.1-1 mg/kg. However, dosage levels are highly  
25       dependent on the nature of the condition, the condition of the patient, the judgment of the practitioner, and the frequency and mode of administration.

#### Screening Methods

30       The compounds of the invention can be synthesized individually using methods known in the art *per se*, or as members of a combinatorial library. In general, the constrained fused ring portion of the molecule, typically containing any R<sup>1</sup> and R<sup>2</sup> substituents is coupled, along with any linking moiety, to the nitrogen of the piperazine or piperidine ring. This ring itself is generally appropriately substituted with (X<sup>2</sup>)<sub>n</sub>-Ar or (X<sup>2</sup>)<sub>n</sub>-Cy prior to this coupling. Typically,

the constrained fused ring-linker portion is supplied containing a suitable electron-withdrawing leaving group, thus effecting the coupling to the ring nitrogen.

In addition to condensing a halogenated derivative of a constrained fused ring moiety to the nitrogen-containing heterocycle, additional conventional ways of condensing the relevant portions of the molecule can be used. For example, a brominated form of appropriately substituted constrained fused ring (containing at least an ethyl group at the ring nitrogen) may be converted to a Grignard reagent which can then be condensed with, for example, the piperidine, or piperazine ring extended at the nitrogen through the moiety  $(CH_2)_nCHO$  wherein n is an integer from 1-4.

Synthesis of combinatorial libraries is now commonplace in the art. Suitable descriptions of such syntheses are found, for example, in Wentworth, Jr., P. *et al. Current Opinion in Biol* (1993) 9:109-115; Salemme, F.R. *et al. Structure* (1997) 5:319-324. The libraries contain compounds with various embodiments of  $R^1$ ,  $R^2$ ,  $R^3$ ,  $X^1$ ,  $X^2$ , Y and Z. These libraries, which contain, as few as 10, but typically several hundred members to several thousand members, may then be screened for compounds which are particularly effective against a specific subtype of calcium channel. In addition, using standard screening protocols, the libraries may be screened for compounds which block additional channels such as sodium channels, potassium channels and the like.

Methods of performing these screening functions are well known in the art. Typically, the channel to be targeted is expressed at the surface of a recombinant host cell such as human embryonic kidney cells. The ability of the members of the library to bind the channel is measured, for example, by the ability of the compound in the library to displace a labeled binding ligand such as the ligand normally associated with the channel or an antibody to the channel. More typically, ability to antagonize the channel is measured in the presence of the appropriate agonist and the ability of the compound to interfere with the signal generated is measured using standard techniques.

In more detail, one method involves the binding of radiolabeled agents that interact with, *e.g.*, the calcium channel and subsequent analysis of equilibrium binding measurements including, but not limited to, on rates, off rates,  $K_d$  values and competitive binding by other molecules. Another method involves the screening for the effects of compounds by electrophysiological assay whereby individual cells are impaled with a microelectrode and currents through the channel are recorded before and after application of the compound of interest. Another method, high-throughput spectrophotometric assay, utilizes loading of the cell lines with a fluorescent dye sensitive to intracellular calcium concentration and subsequent

examination of the effects of compounds on the ability of depolarization by potassium chloride or other means to alter intracellular calcium levels.

The following examples are intended to illustrate but not to limit the invention.

### Example 1


#### Assay of N-type Calcium Channel Blocking Activity

Antagonist activity was measured using whole cell patch recordings on human embryonic kidney cells either stably or transiently expressing rat  $\alpha_{1B} + \alpha_{2b} + \beta_{1b}$  channels with 5 mM barium as a charge carrier.


For transient expression, host cells, such as human embryonic kidney cells, HEK 293 (ATCC# CRL 1573) are grown in standard DMEM medium supplemented with 2 mM glutamine and 10% fetal bovine serum. HEK 293 cells are transfected by a standard calcium-phosphate-DNA coprecipitation method using the rat  $\alpha_{1B} + \beta_{1b} + \alpha_{2\delta}$  N-type calcium channel subunits in a vertebrate expression vector (for example, see *Current Protocols in Molecular Biology*).

After an incubation period of from 24 to 72 hrs the culture medium was removed and replaced with external recording solution (see below). Whole cell patch clamp experiments were performed using an Axopatch 200B amplifier (Axon Instruments, Burlingame, CA) linked to an IBM compatible personal computer equipped with pCLAMP software. Borosilicate glass patch pipettes (Sutter Instrument Co., Novato, CA) were polished (Microforge, Narishige, Japan) to a resistance of about 4 M $\Omega$  when filled with cesium methanesulfonate internal solution (composition in mM: 109 CsCH<sub>3</sub>SO<sub>4</sub>, 4 MgCl<sub>2</sub>, 9 EGTA, 9 HEPES, pH 7.2). Cells were bathed in 5 mM Ba<sup>++</sup> (in mM: 5 BaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 HEPES, 40 tetraethylammonium chloride, 10 glucose, 87.5 CsCl pH 7.2). Current data shown were elicited by a train of 100 ms test pulses at 0.066 Hz from -100 mV and/or -80 mV to various potentials (min. -20 mV, max. +30 mV). Drugs were perfused directly into the vicinity of the cells using a microperfusion system.


Normalized dose-response curves were fit (Sigmaplot 4.0, SPSS Inc., Chicago, IL) by the Hill equation to determine IC<sub>50</sub> values. Steady-state inactivation curves were plotted as the normalized test pulse amplitude following 5 s inactivating prepulses at +10 mV increments. Inactivation curves were fit (Sigmaplot 4.0) with the Boltzman equation,  $I_{peak}$  (normalized) =  $1/(1 + \exp((V - V_h)z/25.6))$ , where V and V<sub>h</sub> are the conditioning and half inactivation potentials, respectively, and z is the slope factor.

Example 2Synthesis of Illustrative Compounds of Formula (1)A. Synthesis of  $\text{MeSO}_2(\text{CH}_2)_6\text{Cl}$ .

1-Chloro-6-hexanol (2 ml, 15 mM) was dissolved in dry THF (40 ml) and the flask purged with nitrogen. To this solution was added DIEA (3.2 ml, 18 mM) followed by the slow addition of methane sulfonyl chloride. The solution was stirred for 5.5 hours. The reaction mixture was extracted with EtOAc and washed with water and 10% HCl. The solution was concentrated under reduced pressure and used without further purification; yield 3.8 g.

B. Synthesis of Formula 1(a).

Phenanthrothiazine (2.0 g, 10 mM) was dissolved in ~70 ml dry THF the flask flushed with nitrogen and cooled to -78°C. To the cooled solution was added n-butyl lithium (4.8 ml, 12 mM) and allowed to stir for 1 hour at -78°C followed by warming to room temperature. The product from the above reaction was added and allowed to stir overnight. The reaction was quenched with ~30 ml water. The THF layer was separated and the aqueous layer extracted with ether. The combined organic layers were then washed with water. The product was purified by silica gel chromatography.



The phenanthrothiazine derivative (0.3 g, 0.95 mM) and the piperazine shown above (0.321 g, 1.76 mM) was dissolved in 5 ml dry THF along with NaI (cat) and K<sub>2</sub>CO<sub>3</sub> (~.5 g) and

heated to 40°C overnight. The reaction mixture was diluted with EtOAc and washed with water (4x) and brine (1x) and the solvent removed under reduced pressure. The residue was purified by column (silica gel hexane/EtOAc) to give the desired product. Some of the compounds in this series required HPLC purification. The compounds were kept out of direct light during the purification and after isolation.

### Example 3

#### Channel Blocking Activities of Various Invention Compounds

Using the procedure set forth in Example 1, various compounds of the invention were tested for their ability to block N-type calcium channels. The results are shown in Tables 1-2, where IC<sub>50</sub> is given in  $\mu$ M (micromolar). Table 1 represents results for compounds of formula (1a) where Z is N and Y is S; and Table 2 represents the results the results for compounds of formula (1b) where Z is N and Y is S. In all cases, I<sup>1</sup>, I<sup>2</sup> and I<sup>3</sup> are 0.

Table 1 Formula (1a), Z is N, Y is S					
X <sup>1</sup>	n	X <sup>2</sup>	Ar	IC <sub>50</sub>	% reversibility
(CH <sub>2</sub> ) <sub>6</sub>	1	-CH <sub>3</sub>		±2	63
(CH <sub>2</sub> ) <sub>6</sub>	1	-CH <sub>2</sub> -CH=CH-	Φ	2-3	20
(CH <sub>2</sub> ) <sub>6</sub>	1	CH <sub>2</sub>	Φ	±2	43
(CH <sub>2</sub> ) <sub>3</sub>	1	-CH <sub>2</sub> CH=CH-	Φ	5	20

Table 2 Formula (1b), Z is N, Y is S					
X <sup>1</sup>	n	X <sup>2</sup>	Cy	IC <sub>50</sub>	% reversibility
(CH <sub>2</sub> ) <sub>3</sub>	1	CH <sub>2</sub>	cyclohexyl	3.2	7
(CH <sub>2</sub> ) <sub>6</sub>	1	CH <sub>2</sub>	cyclohexyl	3.2	9

Example 4Additional Compounds of the InventionIn the following tables,  $l^1 = l^2 = l^3 = 0$ 

Table 3 Formula (1a), Z is CH, Y is S or Z is CH, Y is O or Z is CH, Y is NH or Z is CH, Y is CH <sub>2</sub>			
X <sup>1</sup>	n	X <sup>2</sup>	Ar
(CH <sub>2</sub> ) <sub>6</sub>	1		CH <sub>3</sub>
(CH <sub>2</sub> ) <sub>6</sub>	1	-CH <sub>2</sub> -CH=CH-	Φ
(CH <sub>2</sub> ) <sub>6</sub>	1	CH <sub>2</sub>	Φ
(CH <sub>2</sub> ) <sub>3</sub>	1	-CH <sub>2</sub> CH=CH-	Φ
-CH <sub>2</sub> NHCH <sub>2</sub>	0	-	p-hydroxy phenyl
-(CH <sub>2</sub> ) <sub>4</sub> -	1	-(CH <sub>2</sub> ) <sub>3</sub> -	m-hydroxy phenyl
-CH <sub>2</sub> OCH <sub>2</sub> -	1	-CH <sub>2</sub> CH=CH-	p--carboxy phenyl
-(CH <sub>2</sub> )-	1	-(CH <sub>2</sub> ) <sub>4</sub> -	4-carboxy-3--hydroxy-phenyl
-CH <sub>2</sub> CH=CH-	1	-(CH <sub>2</sub> ) <sub>3</sub> -	4-pyridyl
-CH <sub>2</sub> CH=CH-	1	-(CH <sub>2</sub> ) <sub>3</sub> -	3-pyridyl
-(CH <sub>2</sub> ) <sub>4</sub> -	1	CH	Φ <sub>2</sub>
-CH <sub>2</sub> -NMeCH <sub>2</sub>	1	-(CH <sub>2</sub> ) <sub>2</sub> -	p-nitrophenyl
-CH <sub>2</sub> CH <sub>2</sub> -	1	-CH <sub>2</sub> O CH <sub>2</sub> -	2-pyrimidyl
-(CH <sub>2</sub> ) <sub>3</sub> -	1	-CH <sub>2</sub> CH=CH-	4-pyrimidyl
-CH <sub>2</sub> CH <sub>2</sub> -	1	-(CH <sub>2</sub> ) <sub>3</sub> -	2-pyrrolyl
-(CH <sub>2</sub> ) <sub>6</sub> -	1	-CH <sub>2</sub> NHCH <sub>2</sub> -	4-imidazolyl
-(CH <sub>2</sub> ) <sub>6</sub> -	1	-CH <sub>2</sub> NHCH <sub>2</sub> -	4-thiazolyl

5


Table 4 Formula (1a), Z is N, Y is S			
X <sup>1</sup>	n	X <sup>2</sup>	Ar
-CH <sub>2</sub> NHCH <sub>2</sub>	0	-	p-hydroxy phenyl
-(CH <sub>2</sub> ) <sub>4</sub> -	1	-(CH <sub>2</sub> ) <sub>3</sub> -	m-hydroxy phenyl
-CH <sub>2</sub> OCH <sub>2</sub> -	1	-CH <sub>2</sub> CH=CH-	p--carboxy phenyl
-(CH <sub>2</sub> )-	1	-(CH <sub>2</sub> ) <sub>4</sub> -	4-carboxy-3--hydroxy-phenyl
-CH <sub>2</sub> CH=CH-	1	-(CH <sub>2</sub> ) <sub>3</sub> -	4-pyridyl
-CH <sub>2</sub> CH=CH-	1	-(CH <sub>2</sub> ) <sub>3</sub> -	3-pyridyl
-(CH <sub>2</sub> ) <sub>4</sub> -	1	CH	Φ <sub>2</sub>
-CH <sub>2</sub> -NMeCH <sub>2</sub>	1	-(CH <sub>2</sub> ) <sub>2</sub> -	p-nitrophenyl
-CH <sub>2</sub> CH <sub>2</sub> -	1	-CH <sub>2</sub> O CH <sub>2</sub> -	2-pyrimidyl
-(CH <sub>2</sub> ) <sub>3</sub> -	1	-CH <sub>2</sub> CH=CH-	4-pyrimidyl
-CH <sub>2</sub> CH <sub>2</sub> -	1	-(CH <sub>2</sub> ) <sub>3</sub> -	2-pyrrolyl
-(CH <sub>2</sub> ) <sub>6</sub> -	1	-CH <sub>2</sub> NHCH <sub>2</sub> -	4-imidazolyl
-(CH <sub>2</sub> ) <sub>6</sub> -	1	-CH <sub>2</sub> NHCH <sub>2</sub> -	4-thiazolyl




Table 5 Formula (1a), Z is N, Y is O or Z is N, Y is NH or Z is N, Y is CH <sub>2</sub>			
X <sup>1</sup>	n	X <sup>2</sup>	Ar
(CH <sub>2</sub> ) <sub>6</sub>	1	CH <sub>3</sub>	
(CH <sub>2</sub> ) <sub>6</sub>	1	-CH <sub>2</sub> -CH=CH-	Φ
(CH <sub>2</sub> ) <sub>6</sub>	1	CH <sub>2</sub>	Φ
(CH <sub>2</sub> ) <sub>3</sub>	1	-CH <sub>2</sub> CH=CH-	Φ
-CH <sub>2</sub> NHCH <sub>2</sub>	0	-	p-hydroxy phenyl
-(CH <sub>2</sub> ) <sub>4</sub> -	1	-(CH <sub>2</sub> ) <sub>3</sub> -	m-hydroxy phenyl
-CH <sub>2</sub> OCH <sub>2</sub> -	1	-CH <sub>2</sub> CH=CH-	p--carboxy phenyl
-(CH <sub>2</sub> )-	1	-(CH <sub>2</sub> ) <sub>4</sub> -	4-carboxy-3--hydroxy-phenyl
-CH <sub>2</sub> CH=CH-	1	-(CH <sub>2</sub> ) <sub>3</sub> -	4-pyridyl
-CH <sub>2</sub> CH=CH-	1	-(CH <sub>2</sub> ) <sub>3</sub> -	3-pyridyl
-(CH <sub>2</sub> ) <sub>4</sub> -	1	CH	Φ <sub>2</sub>
-CH <sub>2</sub> -NMeCH <sub>2</sub>	1	-(CH <sub>2</sub> ) <sub>2</sub> -	p-nitrophenyl
-CH <sub>2</sub> CH <sub>2</sub> -	1	-CH <sub>2</sub> O CH <sub>2</sub> -	2-pyrimidyl
-(CH <sub>2</sub> ) <sub>3</sub> -	1	-CH <sub>2</sub> CH=CH-	4-pyrimidyl
-CH <sub>2</sub> CH <sub>2</sub> -	1	-(CH <sub>2</sub> ) <sub>3</sub> -	2-pyrrolyl
-(CH <sub>2</sub> ) <sub>6</sub> -	1	-CH <sub>2</sub> NHCH <sub>2</sub> -	4-imidazolyl
-(CH <sub>2</sub> ) <sub>6</sub> -	1	-CH <sub>2</sub> NHCH <sub>2</sub> -	4-thiazolyl

Claims

1. A method to treat conditions associated with undesired calcium channel activity in a  
 subject which method comprises administering to a subject in need of such treatment a  
 5 compound of the formula



or



or the salts thereof,

wherein Z is N or CH;

wherein n is 0 or 1;

X<sup>1</sup> and X<sup>2</sup> are linkers;

Ar represents one or two substituted or unsubstituted aromatic or heteroaromatic rings,

and

Cy represents one or two substituted or unsubstituted aliphatic cyclic or heterocyclic  
 moieties, or consists of one substituted or unsubstituted aliphatic cyclic or heterocyclic moiety  
 and one substituted or unsubstituted aromatic or heteroaromatic moiety,

Y is O, S, NR or CR<sub>2</sub> where R is H or alkyl (1-6C);

each I<sup>1</sup> and I<sup>2</sup> is independently 0-4;


I<sup>3</sup> is 0 or 1;

each of  $R^1$ ,  $R^2$  and  $R^3$  is independently alkyl (1-6C), aryl (6-10C) or arylalkyl (7-16C) optionally containing 1-4 heteroatoms selected from the group consisting of halo, N, P, O, and S or may independently be halo, OR, SR,  $NR_2$ , OOCR,  $NROCR$ , COR, COOR,  $CONR_2$ ,  $CF_3$ , CN or  $NO_2$ , wherein R is H or alkyl (1-6C), and

wherein the dotted lines represent optional  $\pi$ -bonds, or  
compounds of formulas (1a) or (1b) where  $(X^2)_nAr$  or  $(X^2)_nCy$  is replaced by alkyl (1-6C).

2. The method of claim 1 wherein at least one of  $R^1$ ,  $R^2$  and  $R^3$  is a halo substituent.

3. The method of claim 1 wherein the compound of formula (1) is of the formula (1a)



wherein Y, Z,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $I^1$ ,  $I^2$ ,  $I^3$ ,  $X^1$ ,  $X^2$ , n, and Ar are defined as in claim 1, or wherein  $-(X^2)_n-Ar$  is replaced by alkyl (1-6C).

4. The method of claim 3 wherein Ar represents one or two unsubstituted phenyl moieties.

5. The method of claim 3 wherein n is 1 and  $X^2$  represents a linker which spaces Ar from Z at a distance of 3-20Å.

6. The method of claim 5 wherein n is 1 and  $X^2$  contains at least one heteroatom selected from N and O.

7. The method of claim 5 wherein n is 1, Ar represents one unsubstituted phenyl moiety and  $X^2$  represents  $-(CH_2)_{1-10}-$  or  $-CO(CH_2)_{1-9}-$  or  $-(CH_2)_{1-5}-CH=CH-(CH_2)_{0-3}-$  or  $-NH(CH_2)_{1-8}-$ .


8. The method of claim 5 wherein Ar represents two phenyl moieties and  $X^2$  is of the formula  $-(CH_2)_{0-10}-CH$  or  $-CO(CH_2)_{0-9}CH$ .

9. The method of claim 3 wherein  $-(X^2)_nAr$  is replaced by methyl or ethyl.

10. The method of claim 3 wherein  $l^3$  is 0.

11. The method of claim 3 wherein  $l^1$  and  $l^2$  are 0.

12. The method of claim 1 wherein the compound of formula (1) is of the formula (1b)



wherein Y, Z,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $X^1$ ,  $X^2$ ,  $l^1$ ,  $l^2$  and Cy are as defined in claim 1.

13. The method of claim 12 wherein Cy represents one or two cyclohexyl moieties or a cyclohexyl moiety and a phenyl moiety.

14. The method of claim 12 wherein n is 1 and  $X^2$  represents a linker which spaces Cy from Z at a distance of 3-20Å.

15. The method of claim 12 wherein n is 1 and  $X^2$  contains at least one heteroatom selected from N and O.

16. The method of claim 13 wherein Cy is one cyclohexyl moiety, n is 1 and  $X^2$  represents  $-(CH_2)_{1-10}-$  or  $-CO(CH_2)_{1-9}-$  or  $-(CH_2)_{1-5}-CH=CH-(CH_2)_{0-3}-$  or  $-NH(CH_2)_{1-8}-$ .

17. The method of claim 12 wherein Cy represents two cyclohexyl moieties or a cyclohexyl moiety and a phenyl moiety.

18. The method of claim 17 wherein  $X^2$  is  $-(CH_2)_{0-9}-CH-$  or  $CO(CH_2)_{1-8}CH-$ .

19. The method of claim 12 wherein  $l^3$  is 0.


20. The method of claim 12 wherein  $l^1$  and  $l^2$  are 0.

21. The method of claim 1 wherein  $X^1$  represents a linker which spaces the benzhydryl moiety from N at a distance of 3-20Å.


22. The method of claim 21 wherein  $X^1$  contains at least one heteroatom selected from O and N.

23. The method of claim 20 wherein  $X^1$  represents  $-(CH_2)_{1-10}-$ ,  $-(CH_2)_{1-5}-CH=CH-(CH_2)_{0-3}-$  or  $-(CH_2)_{1-9}CO-$ .

24. A pharmaceutical composition for use in treating conditions characterized by undesired calcium channel activity which composition comprises, in admixture with a pharmaceutically acceptable excipient, a dosage amount of at least one compound of the formula



or



SUBSTITUTE SHEET (RULE 26)

or salts thereof,

wherein Z is N or CH;

wherein n is 0 or 1;

X<sup>1</sup> and X<sup>2</sup> are linkers;

Ar represents one or two substituted or unsubstituted aromatic or heteroaromatic rings,  
and

Cy represents one or two substituted or unsubstituted aliphatic cyclic or heterocyclic moieties, or consists of one substituted or unsubstituted aliphatic cyclic or heterocyclic moiety and one substituted or unsubstituted aromatic or heteroaromatic moiety,

Y is O, S, NR or CR<sub>2</sub> where R is H or alkyl (1-6C);

each l<sup>1</sup> and l<sup>2</sup> is independently 0-4;


l<sup>3</sup> is 0 or 1;

each of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is independently alkyl (1-6C), aryl (6-10C) or arylalkyl (7-16C) optionally containing 1-4 heteroatoms selected from the group consisting of halo, N, P, O, and S or may independently be halo, OR, SR, NR<sub>2</sub>, OOCR, NROCR, COR, COOR, CONR<sub>2</sub>, CF<sub>3</sub>, CN or NO<sub>2</sub>, wherein R is H or alkyl (1-6C), and


wherein the dotted lines represent optional  $\pi$ -bonds, or

compounds of formulas (1a) or (1b) where (X<sup>2</sup>)<sub>n</sub>Ar or (X<sup>2</sup>)<sub>n</sub>Cy is replaced by alkyl (1-6C).

25. A library comprising at least ten different compounds of the formula



or



or salts thereof,

wherein Z is N or CH;

wherein n is 0 or 1;

X<sup>1</sup> and X<sup>2</sup> are linkers;

Ar represents one or two substituted or unsubstituted aromatic or heteroaromatic rings, and

Cy represents one or two substituted or unsubstituted aliphatic cyclic or heterocyclic moieties, or consists of one substituted or unsubstituted aliphatic cyclic or heterocyclic moiety and one substituted or unsubstituted aromatic or heteroaromatic moiety,

Y is O, S, NR or CR<sub>2</sub> where R is H or alkyl (1-6C);

each l<sup>1</sup> and l<sup>2</sup> is independently 0-4;

l<sup>3</sup> is 0 or 1;

each of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is independently alkyl (1-6C), aryl (6-10C) or arylalkyl (7-16C) optionally containing 1-4 heteroatoms selected from the group consisting of halo, N, P, O, and S or may independently be halo, OR, SR, NR<sub>2</sub>, OOCR, NROCR, COR, COOR, CONR<sub>2</sub>, CF<sub>3</sub>, CN or NO<sub>2</sub>, wherein R is H or alkyl (1-6C), and

wherein the dotted lines represent optional  $\pi$ -bonds, or

compounds of formulas (1a) or (1b) where (X<sup>2</sup>)<sub>n</sub>Ar or (X<sup>2</sup>)<sub>n</sub>Cy is replaced by alkyl (1-6C).

26. A method to identify a compound which antagonizes a target channel which method comprises contacting host cells displaying said target channel in the presence of an agonist for said channel and with the members of the library of claim 25;

assessing the ability of the members of the library to affect the response of the channel to its agonist; and

identifying as an antagonist any member of the library which diminishes the response of the channel to its agonist.

27. The method of claim 26 wherein the channel is an ion channel.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01586

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D279/26 A61K31/54 A61P9/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DE 17 70 218 A (SANDOZ AG) 14 October 1971 (1971-10-14) page 4, line 24 - line 26 ---	1-24
Y	FR 1 522 688 A (SANDOZ SA) 26 April 1968 (1968-04-26) page 5, left-hand column, line 14 - line 24 ---	1-24
Y	US 5 428 038 A (S. S. CHATTERJEE ET AL.) 27 June 1995 (1995-06-27) cited in the application column 1 ---	1-24
Y	US 5 703 071 A (N. ITOH ET AL.) 30 December 1997 (1997-12-30) cited in the application column 2 ---	1-24
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

26 April 2001

Date of mailing of the international search report

11/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

## INTERNATIONAL SEARCH REPORT

national Application No

PCT/CA 00/01586

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 646 149 A (M. R. HELLBERG ET AL.) 8 July 1997 (1997-07-08) cited in the application column 1-3	1-24
X	GB 1 425 710 A (JOHN WYETH & BROTHER LTD.) 18 February 1976 (1976-02-18) page 1, line 20 - line 23	1-24
Y	J. L. ARCHIBALD, G. A. BENKE: "Benzamidopiperidines. 2. Heterocyclic Compounds Related to Indoramin" J. MED. CHEM., vol. 17, no. 7, 1974, pages 736-739, XP000973592 * Table I: compound of formula 19 *	1-24
X	M. NAKANISHI ET AL.: "Studies of Piperidine Derivatives. 1" J. MED. CHEM., vol. 13, no. 4, 1970, pages 644-648, XP000574887 tables I, IV, V	1-24
Y	I. TSUTSUI ET AL.: "Role of Calcium Ion in the Excitability and Electrogenic Pump Activity of the Chara corallina Membrane: II. Effects of La(3+), EGTA, and Calmodulin Antagonists on the Current-Voltage Relation" J. MEMBR. BIOL., vol. 96, no. 1, 1987, pages 75-84, XP000995679 page 79; figure 6	1-24
Y	I. TSUTSUI ET AL.: "Role of Calcium Ion in the Excitability and Electrogenic Pump Activity of the Chara corallina Membrane: I. Effects of La(3+), Verapamil, EGTA, W-7, and TFP on the Action Potential" J. MEMBR. BIOL., vol. 96, no. 1, 1987, pages 65-73, XP000995704 table 1	1-24
X	L. TOLDY ET AL.: "Phenthiazinderivate, VI" ACTA CHIM. ACAD. SCI. HUNG., vol. 44, 1965, pages 301-325, XP000996141 page 303	1-24

-/--

## INTERNATIONAL SEARCH REPORT

national Application No  
PCT/CA 00/01586

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	M. GOLINSKI ET AL.: "Synthesis, Binding Affinity, and Cross-Linking of Monodentate Photoactive Phenothiazines to Calmodulin" BIOCONJUGATE CHEM., vol. 6, no. 5, 1995, pages 549-557, XP000995705 * entire document * -----	1-24
A	J.-R. BOISSIER ET AL.: "Etude pharmacologique préliminaire de nouvelles phénothiazines" THERAPIE, vol. 22, no. 2, 1967, pages 375-382, XP000995380 * entire document * -----	1-24

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/CA 00/01586

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 1770218 A	14-10-1971	CH 497458 A	15-10-1970
		AT 292726 B	15-08-1971
		AT 303717 B	15-11-1972
		AT 293372 B	15-09-1971
		AU 5480173 A	12-07-1973
		AU 5480273 A	12-07-1973
		BE 478127 A	
		BE 713802 A	17-10-1968
		BE 750128 A	09-11-1970
		BG 17326 A	25-07-1973
		CH 541575 A	31-10-1973
		CH 557375 A	31-12-1974
		CH 541574 A	15-09-1973
		CH 275190 A	15-05-1951
		DE 2022024 A	19-11-1970
		ES 352822 A	16-11-1969
		FR 7671 M	09-02-1970
		FR 2051509 A	09-04-1971
		FR 956125 A	26-01-1950
		FR 1583822 A	05-12-1969
		GB 673926 A	18-06-1952
		GB 1223314 A	24-02-1971
		GB 1223315 A	24-02-1971
		GB 1300928 A	29-12-1972
		IE 32169 B	02-05-1973
		IE 32170 B	02-05-1973
		IL 29842 A	26-05-1971
		IL 36239 A	23-06-1971
		NL 6804983 A	21-10-1968
		NL 7006739 A	11-11-1970
		NO 124997 B	03-07-1972
		OA 3386 A	15-12-1970
		SE 356520 B	28-05-1973
		SE 361884 B	19-11-1973
		US 2719671 A	04-10-1955
		US 3531480 A	29-09-1970
		IE 34188 B	05-03-1975
		ZA 7002941 A	27-01-1971
FR 1522688 A	26-04-1968	CH 504467 A	15-03-1971
		CH 480363 A	31-10-1969
		CH 476757 A	15-08-1969
		BE 698166 A	08-11-1967
		CA 921473 A	20-02-1973
		DE 1695720 A	13-05-1971
		FR 6647 M	20-01-1969
		GB 1178623 A	21-01-1970
		GB 1178624 A	21-01-1970
		NL 6706369 A	13-11-1967
		OA 2593 A	05-05-1970
		SE 350264 B	23-10-1972
		US 3445464 A	20-05-1969
		CH 504468 A	15-03-1971
		CH 504469 A	15-03-1971
		CH 504470 A	15-03-1971
		ES 340244 A	01-09-1968
		ES 340245 A	01-09-1968
		ES 340246 A	01-09-1968

## INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/CA 00/01586

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 1522688 A		ES 340247 A	01-09-1968
		CH 478820 A	30-09-1969
		ES 340243 A	01-09-1968
US 5428038 A	27-06-1995	DE 4111861 A	15-10-1992
		AT 147736 T	15-02-1997
		AU 658619 B	27-04-1995
		AU 1540392 A	17-11-1992
		CA 2108174 A	12-10-1992
		DE 59207907 D	27-02-1997
		WO 9218493 A	29-10-1992
		EP 0584091 A	02-03-1994
		ES 2097908 T	16-04-1997
		JP 6506922 T	04-08-1994
		MX 9201598 A	01-10-1992
		ZA 9202614 A	30-12-1992
US 5703071 A	30-12-1997	JP 4120069 A	21-04-1992
		JP 4247077 A	03-09-1992
		JP 4295471 A	20-10-1992
		AT 159251 T	15-11-1997
		AU 651629 B	28-07-1994
		AU 8720391 A	30-03-1992
		CA 2087004 A,C	01-03-1992
		DE 69127976 D	20-11-1997
		DE 69127976 T	05-03-1998
		DK 546102 T	02-06-1998
		EP 0546102 A	16-06-1993
		ES 2109276 T	16-01-1998
		FI 930860 A	25-02-1993
		HU 65943 A	29-08-1994
		HU 9500409 A	28-11-1995
		JP 2512656 B	03-07-1996
		JP 6509318 T	20-10-1994
		KR 232324 B	01-12-1999
		NO 305801 B	26-07-1999
		WO 9204338 A	19-03-1992
		US 5594144 A	14-01-1997
US 5646149 A	08-07-1997	AT 199716 T	15-03-2001
		AU 697050 B	24-09-1998
		AU 1336895 A	27-06-1995
		BR 9406080 A	06-02-1996
		CA 2153979 A	15-06-1995
		CN 1117292 A	21-02-1996
		DE 69426871 D	19-04-2001
		EP 0682664 A	22-11-1995
		FI 953748 A	07-08-1995
		JP 8507546 T	13-08-1996
		NO 953093 A	09-10-1995
		WO 9515958 A	15-06-1995
GB 1425710 A	18-02-1976	NONE	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**